Livagen

Livagen (Lys-Glu-Asp-Ala; single-letter code KEDA) is a synthetic tetrapeptide bioregulator developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a liver-targeted member of the broader Khavinson short-peptide bioregulator family. The compound is characterized by three principal pharmacological activities studied across cell culture, animal, and limited human research: (1) epigenetic chromatin remodeling through induction of deheterochromatinization of pericentromeric structural heterochromatin and facultative heterochromatin in lymphocytes and hepatocytes from aged organisms, with consequent reactivation of ribosomal genes and euchromatic loci silenced during aging; (2) potent inhibition of enkephalin-degrading serum peptidases (IC50 approximately 20 micromolar), exceeding the inhibitory potency of established peptidase inhibitors including puromycin, leupeptin, and D-phenylalanyl-alanyl-arginine-p-nitroanilide, without direct interaction with mu or delta opioid receptors; and (3) restoration of protein synthesis rhythms and metabolic function in hepatocyte cultures from aged rats to levels characteristic of young animals at nanomolar concentrations.

The chromatin-remodeling mechanism has been demonstrated in cultured lymphocytes from human subjects aged 75 to 88 years, in which Livagen induced activation of ribosomal genes, decondensation of pericentromeric heterochromatin of chromosomes 1, 9, and 16, and release of genes repressed through age-related condensation of euchromatic regions. This deheterochromatinization effect is shared with other Khavinson bioregulator peptides (Vilon, Epitalon, Cortagen) but appears tissue-preferential for hepatic and lymphoid lineages at the concentrations studied. Molecular modeling studies of the broader Khavinson peptide class suggest that short peptides interact with the nucleosome, histone proteins, and double-stranded DNA through steric and electrostatic complementarity, altering histone modification patterns and the accessibility of regulatory regions to transcription factors.

In experimental models of liver pathology (acute and chronic hepatitis, liver fibrosis), the KEDA tetrapeptide demonstrated hepatoprotective and immunoprotective effects including normalization of total bilirubin, cholesterol, alanine aminotransferase, and aspartate aminotransferase levels; stimulation of tissue repair; and decreased destructive dystrophic processes in liver stroma. The maximal hepatoprotective effect was observed in aged animals, consistent with the bioregulator hypothesis that these peptides primarily restore age-depleted signaling. In aged rat hepatocyte cultures, Livagen restored circahoralian rhythms of protein synthesis to patterns characteristic of young specimens at nanomolar concentrations. A separate line of investigation demonstrated that oral administration of Livagen for two weeks modulated digestive enzyme activity in rats in an age-dependent manner, reducing enzyme activity in young animals while increasing it in old animals toward levels observed in young controls.

The compound is resistant to hydrolysis by small intestinal peptidases and is not degraded to a measurable extent by the peptide hydrolases of the small intestine. Formal pharmacokinetic characterization meeting Western regulatory standards has not been published. The compound is not approved by any major Western regulatory authority (FDA, EMA) and is not registered on ClinicalTrials.gov. The primary research literature originates from Russian and Georgian institutions, and independent Western replication of key findings remains limited. This monograph reviews the chemistry, epigenetic pharmacology, hepatoprotective and digestive enzyme evidence, the limited pharmacokinetic record, sourcing and quality considerations, and a comparative assessment of five alternative hepatoprotective or epigenetic bioregulator compounds against Livagen on five competency standards.